Evolution of lipid nanoparticles as charioteers of Alzheimer's disease therapeutics
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Curcumin's Biomedical Applications · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Therapeutics of Alzheimer's disease: past, present and future10.1016/j.neuropharm.2013.07.004 ↗
2. 2023 Alzheimer's disease facts and figures10.1002/alz.13016 ↗
3. 2019 Alzheimer's disease facts and figures10.1016/j.jalz.2019.01.010 ↗
4. A new strategy for the early detection of Alzheimer disease stages using multifractal geometry analysis based on K-Nearest Neighbor algorithm10.1038/s41598-022-26958-6 ↗
5. The role of amyloid-β oligomers in toxicity, propagation, and immunotherapy10.1016/j.ebiom.2016.03.035 ↗
6. Current and future treatments in Alzheimer disease: an update10.1177/1179573520907397 ↗
7. Dementia prevention, intervention, and care: 2020 report of the LancetCommission10.1016/S0140-6736(20)30367-6 ↗
8. 2020 Alzheimer's disease facts and figures10.1002/alz.12068 ↗
9. Curcumin hybrid molecules for the treatment of Alzheimer's disease: structure and pharmacological activities10.1016/j.ejmech.2023.116070 ↗
10. Protective effects of curcumin and Ginkgo biloba extract combination on a new model of Alzheimer's disease10.1007/s10787-023-01164-6 ↗
11. Alzheimer's disease: recent treatment strategies10.1016/j.ejphar.2020.173554 ↗
12. Drug delivery systems as a strategy to improve the efficacy of FDA-approved Alzheimer's drugs10.3390/pharmaceutics14112296 ↗
13. Drug delivery across the blood–brain barrier10.1021/mp400170b ↗
14. Multifaceted nanoparticles: emerging mechanisms and therapies in neurodegenerative diseases10.1093/brain/awad014 ↗
15. Development of polymeric nanoparticles for blood-brain barrier transfer-strategies and challenges10.1002/advs.202003937 ↗
16. A peptide-based nanocarrier for an enhanced delivery and targeting of flurbiprofen into the brain for the treatment of Alzheimer's disease: an in vitro study10.3390/nano10081590 ↗
17. Aspects of luminescence nanoprobes for thermometry: progress and outlook
18. Tubular nanomaterials for bone tissue engineering10.1039/D3TB00905J ↗
19. Recent development in upconversion nanoparticles and their application in optogenetics: a review10.1016/j.jre.2021.10.003 ↗
20. Graphene-based aerogels for biomedical application10.3390/gels9120967 ↗
21. PLGA core-shell nano/microparticle delivery system for biomedical application10.3390/polym13203471 ↗
22. Highly luminescent biocompatible CsPbBr3@SiO2 core–shell nanoprobes for bioimaging and drug delivery10.1039/D0TB01833C ↗
23. Electrospun fibers for corneal regeneration10.1007/s40135-021-00279-9 ↗
24. Oxidative stress modulating nanomaterials and their biochemical roles in nanomedicine10.1039/D4NH00171K ↗
25. Nanoparticles as drug delivery systems: a review of the implication of nanoparticles' physicochemical properties on responses in biological systems10.3390/polym15071596 ↗
26. An insight to brain targeting utilizing polymeric nanoparticles: effective treatment modalities for neurological disorders and brain tumor
27. Safe nanoparticles: are we there yet?10.3390/ijms22010385 ↗
28. Fabrication and characterization of PLGA nanoparticles encapsulating large CRISPR–Cas9 plasmid10.1186/s12951-019-0564-1 ↗
29. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic10.1615/CritRevTherDrugCarrierSyst.v26.i6.10 ↗
30. Nanoparticle formulations in the diagnosis and therapy of Alzheimer's disease10.1016/j.ijbiomac.2019.02.156 ↗
31. Potential of solid lipid nanoparticles in brain targeting10.1016/j.jconrel.2007.12.018 ↗
32. Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art10.1016/j.ejpb.2014.05.004 ↗
33. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases10.1016/j.jconrel.2017.08.033 ↗
34. Engineered solid lipid nanoparticles and nanostructured lipid carriers as new generations of blood-brain barrier transmitters10.1021/acschemneuro.1c00540 ↗
35. Proof of concept studies to confirm the delivery of curcumin loaded solid lipid nanoparticles (C-SLNs) to brain10.1016/j.ijpharm.2013.03.046 ↗
36. Molecular pathogenesis and interventional strategies for Alzheimer's disease: promises and pitfalls10.1021/acsptsci.9b00104 ↗
37. Nanotherapeutics for Alzheimer's disease with preclinical evaluation and clinical trials: challenges, promises and limitations10.2174/1567201818666210910162750 ↗
38. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo10.1038/nm1438 ↗
39. Nanotechnological strategies for nerve growth factor delivery: therapeutic implications in Alzheimer's disease10.1016/j.phrs.2017.03.020 ↗
40. The revitalized tau hypothesis on Alzheimer's disease10.1016/j.arcmed.2010.03.007 ↗
41. Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults10.1212/WNL.0000000000004392 ↗
42. Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease10.1212/WNL.0000000000004887 ↗
43. Tau imaging in Alzheimer's disease diagnosis and clinical trials10.1007/s13311-016-0490-y ↗
44. CryoET of β-amyloid and tau within postmortem Alzheimer's disease brain10.1038/s41586-024-07680-x ↗
45. The history of the cholinergic hypothesis10.1016/j.bbr.2009.12.044 ↗
46. Tacrine: first drug approved for Alzheimer's disease10.1177/106002809402800612 ↗
47. Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor10.1254/jjp.89.7 ↗
48. Therapeutic potential of multifunctional derivatives of cholinesterase inhibitors10.2174/1570159X19666201218103434 ↗
49. Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management10.1016/j.jconrel.2024.01.047 ↗
50. Use of memantine for the treatment of dementia10.1586/ern.11.132 ↗
51. Role of aducanumab in the treatment of Alzheimer's disease: challenges and opportunities10.2147/CIA.S325026 ↗
52. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: a systematic review10.1177/03946320231209839 ↗
53. Tacrine derivatives in neurological disorders: focus on molecular mechanisms and neurotherapeutic potential10.1155/2022/7252882 ↗
54. Donepezil for Alzheimer's disease10.1586/14737175.7.10.1243 ↗
55. Donepezil for dementia due to Alzheimer's disease
56. Cholinergic modulation of the hippocampal region and memory function10.1111/jnc.14052 ↗
57. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months10.1002/gps.1864 ↗
58. Rivastigmine for Alzheimer's disease10.1586/14737175.5.5.563 ↗
59. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease10.1038/nature19323 ↗
60. BAN2401 shows stronger binding to soluble aggregated amyloid-beta species than aducanumab
61. Biotechnological advances in resveratrol production and its chemical diversity10.3390/molecules24142571 ↗
62. Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: a review10.1049/nbt2.12127 ↗
63. Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress10.1016/j.ijpharm.2009.03.021 ↗
64. Resveratrol as a therapeutic agent for Alzheimer's disease10.1155/2014/350516 ↗
65. Resveratrol rescues tau-induced cognitive deficits and neuropathology in a mouse model of tauopathy10.2174/1567205016666190801153751 ↗
66. Mechanism of quercetin therapeutic targets for Alzheimer disease and type 2 diabetes mellitus10.1038/s41598-021-02248-5 ↗
67. Use of curcumin in diagnosis, prevention, and treatment of Alzheimer's disease10.4103/1673-5374.230303 ↗
68. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo10.1074/jbc.M404751200 ↗
69. Mechanistic insights of curcumin interactions with the core-recognition motif of β-amyloid peptide10.1021/jf4000709 ↗
70. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio10.1007/s11095-014-1593-y ↗
71. Berberine: a potential multipotent natural product to combat Alzheimer's disease10.3390/molecules16086732 ↗
72. Bioassays guided isolation of berberine from Berberis lycium and its neuroprotective role in aluminium chloride induced rat model of Alzheimer's disease combined with in silico molecular docking10.1371/journal.pone.0286349 ↗
73. Berberine reduces Aβ(42) deposition and tau hyperphosphorylation via ameliorating endoplasmic reticulum stress
74. Neuroprotective properties of berberine: molecular mechanisms and clinical implications10.3390/antiox12101883 ↗
75. Berberine improves cognitive impairment by promoting autophagic clearance and inhibiting production of β-amyloid in APP/tau/PS1 mouse model of Alzheimer's disease10.1016/j.exger.2017.02.004 ↗
76. Berberine inhibits the release of glutamate in nerve terminals from rat cerebral cortex10.1371/journal.pone.0067215 ↗
77. Lactoferrin modification of berberine nanoliposomes enhances the neuroprotective effects in a mouse model of Alzheimer's disease10.4103/1673-5374.344841 ↗
78. Pharmacological review on Asiatic acid and its derivatives: a potential compound10.1177/2472630317751840 ↗
79. Neuroprotective mechanisms of Asiatic acid10.1016/j.heliyon.2023.e15853 ↗
80. Neuroprotective effect of nose-to-brain delivery of Asiatic acid in solid lipid nanoparticles and its mechanisms against memory dysfunction induced by amyloid beta(1-42) in mice10.1186/s12906-023-04125-2 ↗
81. The blood-brain barrier in health and chronic neurodegenerative disorders10.1016/j.neuron.2008.01.003 ↗
82. The blood-brain barrier: an overview: structure, regulation, and clinical implications10.1016/j.nbd.2003.12.016 ↗
83. The blood–brain barrier: structure, regulation, and drug delivery10.1038/s41392-023-01481-w ↗
84. The large apparent work capability of the blood-brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat10.1002/ana.410010502 ↗
85. A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity10.1186/s12987-020-00230-3 ↗
86. Solid Lipid Nanoparticles (SLNs): an advanced drug delivery system targeting Brain through BBB10.3390/pharmaceutics13081183 ↗
87. Key for crossing the BBB with nanoparticles: the rational design10.3762/bjnano.11.72 ↗
88. A comprehensive review on recent preparation techniques of liposomes10.1080/08982104.2019.1668010 ↗
89. Nanotechnology: a promising approach for delivery of neuroprotective drugs10.3389/fnins.2020.00494 ↗
90. Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application10.3390/pharmaceutics14030543 ↗
91. Liposomes: structure, composition, types, and clinical applications10.1016/j.heliyon.2022.e09394 ↗
92. Getting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrier10.2147/IJN.S117210 ↗
93. Ligand-functionalized nanoliposomes for targeted delivery of galantamine10.1016/j.ijpharm.2013.03.037 ↗
94. Dermal pharmacokinetics of rivastigmine-loaded liposomes: an ex vivo-in vivo correlation study10.1080/08982104.2020.1787440 ↗
95. Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil
96. Nano-niosomes as nanoscale drug delivery systems: an illustrated review10.1016/j.jconrel.2014.04.015 ↗
97. Niosome: a future of targeted drug delivery systems10.4103/0110-5558.76435 ↗
98. Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery10.3390/pharmaceutics11020055 ↗
99. Niosome: a promising nanocarrier for natural drug delivery through blood-brain barrier
100. Current advances in specialised niosomal drug delivery: manufacture, characterization and drug delivery applications10.3390/ijms23179668 ↗